Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Abigail Lang, Wajiha Kazmi, Jonathan J Lyons

Abstract readReview

In one paragraph

Review in Immunology and allergy clinics of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abigail LangDivision of Allergy and Immunology, Ann and Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics at Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Wajiha KazmiDepartment of Internal Medicine, Zucker School of Medicine, Hofstra/Northwell, Hempstead, NY, USA.

Jonathan J LyonsDivision of Allergy & Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA; Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA. Electronic address: j3lyons@health.ucsd.edu.

Funding

TPSAB1-derived tryptases promote myeloproliferation and anaphylaxisR00AI138586 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jonathan Lyons · 2024 to 2026

$2.3M

NIAID NIH HHS R00 AI138586

6 · The paper itself

Abstract

Hereditary alpha-tryptasemia (HαT) is a common autosomal dominant genetic trait that results from increased copy numbers of the TPSAB1 gene encoding α-tryptase. Studies have shown that increased relative α-tryptase expression can modify mast-cell-mediated reactions and contribute to increased severity of anaphylaxis. HαT is an independent risk modifier for reaction severity in patients with Hymenoptera venom allergy and systemic mastocytosis. Additionally, there is emerging evidence that HαT and α-tryptase expression more generally are also associated with increased risk of severe reactions to other allergens. Tryptase genotyping may be a promising biomarker for risk stratification of IgE-mediated allergic reaction severity in the future.

Indexed as

AnaphylaxisTryptasesAllergensAnimalsGenetic Predisposition to DiseaseHumansImmunoglobulin EMast Cell Activation SyndromeMast CellsRisk FactorsSeverity of Illness IndexVenom HypersensitivityAllergensImmunoglobulin ETPSAB1 protein, humanTryptasesAnaphylaxisDrug allergyFood allergyHereditary alpha-tryptasemiaMastocytosis

Identifiers

PMID41932753

DOI10.1016/j.iac.2026.01.010

PMCPMC13599422

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.